Pioglitazone Hydrochloride Used for Diabetes Medication

Synonyms:Pioditazone hydrochloride;5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzylidine]-2,4-thiazolidinedionehydrochloride;AD-4833;pioglitazone hydrochioride;PIODLITAZONE HYDROCHLORIC;5-{4-[2-(5-ETHYL-PYRIDIN-2-YL)-ETHOXY]-BENZYL}-THIAZOLIDINE-2,4-DIONE HCL;5-{4-[2-(5-Ethyl-pyridin-2-yl)-ethoxy]-benzyl}-;5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride

CAS:112529-15-4
MF:C19H21ClN2O3S
MW:392.9
Product Categories:Active Pharmaceutical Ingredients;Antidiabetic;
Diabetes;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur Compounds;API's;Pioglitazone;Inhibitor;API;Cardiovascular Series
Melting point: 193-194°C
Storage temp.: Desiccate at RT
Chemical Properties: Colourless Prisms
Uses: euglycemic agent
Uses: Used as an antidiabetic .

Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin.The main study that looked at the medication, however, found no statistically significant difference in the main cardiovascular outcomes that were looked at.

The secondary outcome of death from all causes, myocardial infarction, and stroke were lower. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.

Desscription:


1. Pioglitazone hydrochloride is used for the treatment of diabetes mellitus type 2 either alone or in combination with a sulfonylurea, m inThere was, however, no statistically significant difference in the main outcomes studied.

2. Pioglitazone hydrochloride has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.Chemical Properties Colourless Prisms

3.Pioglitazone is a prescription drug of the thiazolidinedione (TZD) class with hypoglycemic (antihyperglycemic, antidiabetic) action to treat diabetes. While pioglitazone does decrease blood sugar levels, studies on the main cardiovascular outcomes have not yielded statistically significant results.

4.Its cardiovascular safety profile compares favorably with that of rosiglitazone, which was withdrawn from some markets after concerns about an increased risk of cardiac events. Pioglitazone has been found to be associated with bladder tumors and has been withdrawn in some countries.